|
|
1201 Clopper Road
Gaithersburg, MD 20878 USA
phone:(301) 944-7000
fax:240-632-7121
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.digene.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Gene-based testing systems for screening, monitoring and diagnosis of diseases.(Merged with Qiagen) |
|
| Management |
| Daryl J. Faulkner, Chief Executive Officer and President; James H. Godsey, Ph.D., Senior Vice President, Research & Development; Attila T. L?rincz, Ph.D., Chief Scientific Officer, Science & Technology; Robert McG. Lilley, Senior Vice President, Global Sales & Marketing; Belinda O. Patrick, Senior Vice President, Manufacturing Operations; Donna Marie Seyfried, Vice President, Business Development; Joseph P. Slattery, Chief Financial Officer and Senior Vice President; C. Douglas White, Senior Vice President, Sales and Marketing - Americas and Asia Pacific |
| |
|
|
|
|
|
| Keywords |
| diagnostics, gene based testing, screening, cancer, advamed, Qiagen |
|
|
|
| Description |
|
Digene Corporation develops, manufactures and markets proprietary gene-based testing systems for the screening, monitoring and diagnosis of human diseases. Its primary focus is in women's cancers and infectious diseases. Has the only FDA-approved test for the human papillomavirus (HPV), the primary cause of cervical cancer. |
|
| Products / Services |
Digene markets the only FDA'approved test for detection of high'risk types of the human papillomavirus (HPV), the primary cause of cervical cancer. Digene's hc2 High'Risk HPV DNA Test? was first approved for follow'up evaluation in women with inconclusive Pap'test results. In 2003, the FDA also approved this test, now known as "The Digene? HPV Test" or DNAwithPap? Test, for routine screening, along with the Pap, in women age 30 and older. The Digene HPV Test screens for presence or absence of 13 types of high'risk HPV that are most associated with cervical cancer
|
|
| Technology / Differentiation |
| Digene's proprietary Hybrid Capture? technology serves as the platform for Digene's signal-amplified, nucleic acid tests. The Hybrid Capture platform utilizes specific RNA probes, hybridization, antibody capture and signal amplification to allow rapid, standardized gene testing in virtually any laboratory setting. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
